Activity of fosfomycin against extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae;Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 10, 2006, Pages 613-616

  De Cueto, Marina ^a   Hernández, José R ^b   López Cerero, Lorena ^a   Morillo, Concepción ^b   Pascual, Álvaro ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Community acquired infection; Extended spectrum beta lactamases; Resistance; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; ESCHERICHIA COLI; GENE SEQUENCE; ISOELECTRIC FOCUSING; KLEBSIELLA PNEUMONIAE; NONHUMAN; POLYMERASE CHAIN REACTION; URINARY TRACT INFECTION;

EID: 33846442426     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095372     Document Type: Article

References (26)

1. Bradford PA. Extended spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
2. Asensio A, Oliver A, González-Diego P, Baquero F, Pérez-Díaz JC, Ros P, et al. Outbreak of multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis. 2000;30:55-60.
3. Bermejo J, Lesnaberes P, Arseni N, Gianello M, Notario R, Borda N, et al. Factores de riesgo asociados con las infecciones debidas a Klebsiella pneumoniae resistentes a ceftazidima. Enferm Infecc Microbiol Clin. 2003;21: 72-6.
4. Gniadkowski M, Evolution and epidemiology of extended spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect. 2001;7:597-608.
5. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infection by extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-91.
6. Hernández JR, Pascual A, Cantón R, Martínez- Martínez L. Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en hospitales españoles (proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin. 2003;21:77-82.
7. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goznes H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended spectrum betalactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30:473-78.
8. Schwaber MJ, Navon-Venezia S, Carmelli Y. High level of antimicrobial co-resistance among extended-spectrum betalactamase-producing Enterobacteriaceae. Antimicrob Agent Chemother. 2005;49:2137-9.
9. Andreu A, Alos JI, Gobernado M, Marco F, De la Rosa M, García-Rodríguez JA. Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja en la comunidad. Estudio nacional multi-céntrico. Enferm Infecc Microbiol Clin. 2005;23;1-3.
10. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003;22:853-9.
11. Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999;43:137-40.
12. De Cueto M, López L, Hernández JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother. 2006;50:368-70.
13. Romero L, López L, Rodríguez Baño J, Martínez-Martínez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases. Clin Microbiol Infect. 2005;11(8):25-31.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 15th informational supplement. Approved standard M100-S15. Wayne: CLSI; 2005.
15. Bou G, Cartelle M, Tomás M, Canle D, Molina F, Moure R, et al. Identification and broad dissemination of the CTX-M-14 beta-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol. 2002;40:4030-6.
16. Rodríguez-Baño J, Navarro MD, Romero L, Martínez- Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended spectrum betalactamase producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089-94.
17. Hernández JR, Cantón R, Martínez-Martínez L, Coque TM, Pascual A, and Spanish group for nosocomial infections (GEIH). Escherichia coli and Klebsiella pneumoniae producing extended spectrum β-lactamases in Spain: a nationwide study. Antimicrob Agents Chemother. 2005;21:77-82.
18. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended spectrum beta-lactamases. Importance of community isolates with blaCTX-M genes. Clin Infect Dis. 2004;38:1736-41.
19. Hooton TM. The current management strategies for community acquired urinary tract infection. En: Stamm WE, editor. Urinary tract infection. Infectious Disease Clinics of North America. 2003;17:303-31.
20. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G, and the Italian ESBL study group. Occurrence of extended spectrum beta-lactamases in members of the family enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002;46:196-202.
21. Johnson BM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin/tazobactam: emphasis on its activity against resistant organisms populations and generally untested species causing community acquired respiratory tract infections. Diagn Microbiol Infect Dis. 2002;43:49-60.
22. Alhambra A, Cuadros JA, Cacho J, Gomes Garcés JL, Alós JI. In vitro susceptibility of recent antibiotic resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004;53:1090-4.
23. Ungheri D, Albini E, Belluco G. In vitro susceptibility of quinolone resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother. 2002; 14:237-40.
24. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003;22 Suppl 2:79-83.
25. Manges AR, Johson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infection caused by a multidrug resistant Escherichia coli clonal group. N Engl J Med. 2001;345:1007-13.
26. Moreno E, Prats G, Sabate M, Pérez T, Jonson JR, Andreu A. Quinolone, fluoroquinolone, and trimethoprim-sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J Antimicrob Chemother. 2006;57:204-11.